Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2012

View Archived Issues

Rexahn Pharmaceuticals obtains clearance for first-in-human RX-3117 study

Tesetaxel is active in patients with gastroesophageal cancer

Therapeutic investigation of dacomitinib expands to gastric cancer

MLN-8237 investigated with cisplatin in gastrointestinal cancer models

Alantos identifies potent disease-modifying candidate osteoarthritis drug

BrainStorm reports initial safety and efficacy data on NurOwn stem cell product

Vivalis and Sanofi Pasteur extend collaboration

Noscira completes randomization in tideglusib study

New Japanese approval of controlled-release paroxetine product

Trimel Pharmaceuticals advances phase III CompleoTRT study

Novelos Therapeutics starts phase Ib trial of radiotherapeutic agent in advanced solid tumors

Bristol-Myers Squibb patents novel chemokine CCR1 receptor ligands

Novel chemokine CCR2 receptor antagonists disclosed by Janssen

Chilean team presents new biomarker of gastric cancer progression

New insulin-like growth factor 1 receptor antagonists designed in Japan

FOB Synthesis claims new antibacterial agents

New PET imaging agents synthesized by Bracco Imaging

Trimesta studied in new phase II trial for cognitive dysfunction in MS

FDA clears clinical testing of oral epidermal growth factor receptor mutant-selective inhibitor

Hybrigenics files clinical trial application for inecalcitol in CLL

New JTE-013 analogues prepared in Italy

Ferrer cleared to begin phase III trials of ozenoxacin cream

Cell Therapeutics anticipates CHMP's opinion on Pixuvri MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 13, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
GWAS identifies variant associated with diabetic retinopathy and susceptibility to T2D
BioWorld Science
Scientists at the University of Nottingham Ningbo China and collaborators aimed to identify genetic variants associated with diabetic retinopathy.